External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience NANOS 2024
Roche and Genentech at

NANOS 2024

March 02 - March 07
Honolulu, USA
nanosweb.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Mar 3 / Roche and Genentech
Satralizumab▼ treatment in adults with AQP4-IgG–seropositive neuromyelitis optica spectrum disorder: a retrospective case series
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune neuroinflammatory disease. Satralizumab▼ is a humanised monoclonal recycling antibody against the interleukin 6 receptor with demonstrated safety and efficacy in patients with NMOSD in 2 randomized, placebo-controlled Phase III clinical trials (SAkuraSky [NCT02028884] and SAkuraStar [NCT02073279]). The objective of this real-world, retrospective case series was to describe the experience with satralizumab▼ in adults with AQP4-IgG+ NMOSD in clinical practice.
Neuroscience Neuromyelitis Optica NANOS-2024
10:00 PM
Duration 150mins Honolulu, USA
Satralizumab▼ treatment in adults with AQP4-IgG–seropositive neuromyelitis optica spectrum disorder: a retrospective case series
Hesham Abboud, Brian Steingo, Diana Vargas, Julie Patel, Nancy Nealon, Mary Alissa Willis, Yang Mao-Draayer, Dmitry Khaitov, Jose Avila Ornelas, Adnan Subei, Clifford Reed, William S. Baek, Michelle Tsai, Angie Kim, Ahmed Z. Obeidat, Krupa Pandey, Michael Levy, Negar Molazadeh, Robert Shin, Rebecca Romero, Paige Goulette, Rosemarie Walch, Jeanie Coté, Robert Pace, Buse Sengul, Lisa Ferayorni, Shervin Gholizadeh
Neuroscience | Neuromyelitis Optica

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.